The Vanguard Group, Inc. recently announced the acquisition of new stake in ImmunityBio Inc (NASDAQ:IBRX). The institutional investor has increased its shareholding in the Healthcare company by 43.20% to 14.37 million shares with purchase of 4.34 million shares. This fresh investment now brings its stake to 2.15% valued currently at $72.15 million. In addition, BlackRock Fund Advisors raised its holdings by 1.31 million to 9.92 million shares.
Currently, there are 421.57M common shares owned by the public and among those 130.82M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 16 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 15 of these insider trades were purchases, accounting for 209,661,029 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 42,192 shares.
The top 3 mutual fund holders in ImmunityBio Inc are SPDR S&P Biotech ETF, Vanguard Total Stock Market ETF, and iShares Russell 2000 ETF. SPDR S&P Biotech ETF owns 6.56 million shares of the company’s stock, all valued at over $32.95 million. The company sold 63360.0 shares recently to bring their total holdings to about 0.98% of the shares outstanding. Vanguard Total Stock Market ETF sold -1.57 million shares to see its total holdings shrink to 4.26 million shares valued at over $21.36 million and representing 0.64% of the shares outstanding. iShares Russell 2000 ETF sold 9378.0 shares to bring its total holdings to over 3.54 million shares at a value of $17.78 million. iShares Russell 2000 ETF now owns shares totaling to 0.53% of the shares outstanding.
However, the script later moved the day high at 3.8000, down -7.95%. The company’s stock has a 5-day price change of -10.88% and 158.46% over the past three months. IBRX shares are trading -33.07% year to date (YTD), with the 12-month market performance down to -27.11% lower. It has a 12-month low price of $1.21 and touched a high of $6.93 over the same period. IBRX has an average intraday trading volume of 6.37 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -22.59%, -16.64%, and 21.25% respectively.
Institutional ownership of ImmunityBio Inc (NASDAQ: IBRX) shares accounts for 7.51% of the company’s 421.57M shares outstanding. Mutual fund holders own 5.54%, while other institutional holders and individual stakeholders account for 80.37% and 1.97% respectively.
It has a market capitalization of $2.24B and a beta (3y monthly) value of 1.02. The earnings-per-share (ttm) stands at -$1.05. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.52% over the week and 9.42% over the month.
Analysts forecast that ImmunityBio Inc (IBRX) will achieve an EPS of -$0.18 for the current quarter, -$0.16 for the next quarter and -$0.68 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.18 while analysts give the company a high EPS estimate of -$0.18. Comparatively, EPS for the current quarter was -$0.28 a year ago. Earnings per share for the fiscal year are expected to increase by 10.58%, and 26.88% over the next financial year. EPS should shrink at an annualized rate of -1.70% over the next five years, compared to 2.79% over the past 5-year period.
Looking at the support for the IBRX, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on May 12, 2023, with the firm’s price target at $10-$4.
